Document Detail


Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement.
MedLine Citation:
PMID:  11413077     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Arterial recanalization precedes clinical improvement or may lead to hemorrhage or reperfusion injury. Speed of clot lysis was not previously measured in human stroke. METHODS AND RESULTS: Transcranial Doppler (TCD) and the National Institutes of Health Stroke Scale (NIHSS) were used to monitor consecutive patients receiving intravenous tissue plasminogen activator (tPA), before tPA bolus and at 24 hours. Patients with complete or partial recanalization of the middle cerebral or basilar artery on TCD were studied. Recanalization was classified a priori as sudden (abrupt appearance of a normal or stenotic low-resistance signal), stepwise (flow improvement over 1 to 29 minutes), or slow (>/=30 minutes). Recanalization was documented in 43 tPA-treated patients (age 68+/-17 years; NIHSS score 16.8+/-6, median 15 points). tPA bolus was given at a mean of 135+/-61 minutes after symptom onset. Recanalization began at a median of 17 minutes and was completed at 35 minutes after tPA bolus, with mean duration of recanalization of 23+/-16 minutes. Recanalization was sudden in 5, stepwise in 23, and slow in 15 patients. Faster recanalization predicted better short-term improvement (P=0.03). At 24 hours, 80%, 30%, and 13% of patients in these respective recanalization groups had NIHSS scores of 0 to 3. Symptomatic hemorrhage occurred in only 1 patient, who had stepwise recanalization 5.5 hours after stroke onset. Slow or partial recanalization with dampened flow signal was found in 53% of patients with total NIHSS scores >10 points at 24 hours (P=0.01). Complete recanalization (n=25) occurred faster (median 10 minutes) than partial recanalization (n=18; median 30 minutes; P=0.0001). CONCLUSIONS: Rapid arterial recanalization is associated with better short-term improvement, mostly likely because of faster and more complete clot breakup with low resistance of the distal circulatory bed. Slow (>/=30 minutes) flow improvement and dampened flow signal are less favorable prognostic signs. These findings may be evaluated to assist with selection of patients for additional pharmacological or interventional treatment.
Authors:
A V Alexandrov; W S Burgin; A M Demchuk; A El-Mitwalli; J C Grotta
Related Documents :
10356097 - Prospective randomized trial of bilateral carotid endarterectomies: primary closure ver...
11108767 - Stent angioplasty for cervical carotid artery stenosis in high-risk symptomatic nascet-...
16882637 - Location and size of infarct on functional outcome of noncardioembolic ischemic stroke.
23143737 - Prone positioning of obese patients for colonoscopy results in shortened cecal intubati...
23182957 - Long-term follow-up of sprengel's deformity treated with the woodward procedure.
21337557 - Functional ability and physical activity in children and young adults after limb-salvag...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  103     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-06-19     Completed Date:  2001-07-19     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2897-902     Citation Subset:  AIM; IM    
Affiliation:
Center for Noninvasive Brain Perfusion Studies, Stroke Treatment Team, University of Texas-Houston Medical School, Houston, Texas, USA. avalexandrov@worldnet.att.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Basilar Artery / pathology,  ultrasonography
Blood Flow Velocity / drug effects
Hemorrhage / chemically induced
Humans
Injections, Intravenous
Intracranial Thrombosis / classification,  diagnosis*,  drug therapy*,  physiopathology
Middle Cerebral Artery / pathology,  ultrasonography
Predictive Value of Tests
Prognosis
Severity of Illness Index
Time Factors
Tissue Plasminogen Activator / administration & dosage*,  adverse effects
Treatment Outcome
Ultrasonography, Doppler, Transcranial*
Vascular Patency / drug effects
Grant Support
ID/Acronym/Agency:
1 K23 NS02229-01/NS/NINDS NIH HHS; 1-T32-NS07412-O1A1/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t...
Next Document:  Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women.